AR121905A1 - Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv - Google Patents

Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv

Info

Publication number
AR121905A1
AR121905A1 ARP210101072A ARP210101072A AR121905A1 AR 121905 A1 AR121905 A1 AR 121905A1 AR P210101072 A ARP210101072 A AR P210101072A AR P210101072 A ARP210101072 A AR P210101072A AR 121905 A1 AR121905 A1 AR 121905A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
haloalkyl
independently selected
occurrence
Prior art date
Application number
ARP210101072A
Other languages
English (en)
Inventor
Thilo Heckrodt
Michael Walker
Min Zhong
Original Assignee
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc filed Critical Assembly Biosciences Inc
Publication of AR121905A1 publication Critical patent/AR121905A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thin Film Transistor (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)

Abstract

La presente divulgación proporciona, en parte, compuestos de carboxamida de heteroarilo de 5 miembros, y composiciones farmacéuticas de estos, útiles para la interrupción del ensamblaje de la proteína del núcleo de HBV y métodos de tratamiento de la infección de la hepatitis B (HBV). Reivindicación 1: En un aspecto, la presente divulgación proporciona un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable de este, caracterizado porque: L es alquilenoC₁₋₄ o haloalquilenoC₁₋₄; L¹ y L² son independientemente un enlace, alquilenoC₁₋₆, O, NRᶜ, C(O), C(O)O, C(O)NRᶜ, S(O)ₜ o S(O)ₜNRᶜ; X¹ es NRˣ¹; X³ es CR⁴R⁸; X⁴ y X⁶ son independientemente O ó S; X⁵ es O, S o NR⁰; Rᵃ, Rᵇ y Rᶜ se seleccionan independientemente para cada aparición del grupo que consiste en hidrógeno, alquiloC₁₋₆, haloalquiloC₁₋₆ y monocicloalquiloC₃₋₆; Rᵈ es hidrógeno, OH, alquiloC₁₋₆ o alcoxiC₁₋₆; Rˣ¹ es hidrógeno, alquiloC₁₋₄, alqueniloC₁₋₄, alquiniloC₁₋₄, haloalquiloC₁₋₄ o monocicloalquiloC₃₋₆; o Rˣ¹ y R² juntos forman un grupo -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH₂CH₂O-, -CH₂OCH₂-, -CH₂CH₂CH₂O-, -CH₂CH₂OCH₂-, -CH₂CH₂-NH-, -CH₂NHCH₂-, -CH₂CH₂CH₂NH- o -CH₂CH₂NHCH₂-; R⁰ᵃ se selecciona independientemente para cada aparición del grupo que consiste en hidrógeno, halógeno, OH, CN, NO₂, RᵃRᵇN-, alquiloC₁₋₄ y haloalquiloC₁₋₄; R⁴ᵃ y R⁶ᵃ son independientemente hidrógeno o alquiloC₁₋₄; R⁰, R⁶ y R¹¹ se seleccionan independientemente para cada aparición del grupo que consiste en hidrógeno, halógeno, OH, CN, NO₂, oxo, RᵈN=, hidrazino, formilo, azido, sililo, siloxi, HOC(O)-, RᵃRᵇN-, RᵃRᵇNS(O)ₜ-, alquiloC₁₋₆, alqueniloC₂₋₆, alquiniloC₂₋₆, haloalquiloC₁₋₆, hidroxialquiloC₁₋₆-, RᵃRᵇNalquiloC₁₋₆-, HOC(O)alquiloC₁₋₆-, RᵃRᵇNalquiloC₁₋₆NRᶜ-, alquiloC₁₋₆NRᵃalquilo C₁₋₆NRᶜ-, alcoxiC₁₋₆, haloalcoxiC₁₋₆, hidroxialcoxiC₁₋₆-, RᵃRᵇNalcoxiC₁₋₆-, alcoxiC₁₋₆alquiloC₁₋₆-, haloalcoxiC₁₋₆alquiloC₁₋₆-, RᵃRᵇNC(O)-, alquiloC₁₋₆C(O)-, alcoxiC₁₋₆C(O)-, alquiloC₁₋₆C(O)O-, alquiloC₁₋₆S(O)q-, alquiloC₁₋₆S(O)ₜNRᶜ-, alquiloC₁₋₆S(O)ₜalquiloC₁₋₆-, alquiloC₁₋₆S(O)ₜNRᵃalquiloC₁₋₆-, cicloalquiloC₃₋₆S(O)ₜalquiloC₁₋₆-, alquiloC₁₋₆C(O)alquiloC₁₋₆- y alquiloC₁₋₆C(O)OalquiloC₁₋₆-; R¹ es un fenilo o heteroarilo monocíclico de 5 - 6 miembros, donde el fenilo o heteroarilo monocíclico de 5 - 6 miembros está opcionalmente sustituido con uno, dos o tres grupos R¹¹ seleccionados independientemente; R² y R⁸ se seleccionan independientemente del grupo que consiste en hidrógeno, halo, CN, OH, RᵃRᵇN, alquiloC₁₋₄, haloalquiloC₁₋₄, monocicloalquiloC₃₋₅, alcoxiC₁₋₄ y haloalcoxiC₁₋₄; R³ es un resto de fórmula (2); R⁴ es R⁵-L¹-, R⁶ o R⁹; R⁵ es un resto de fórmula (3); R⁹ es R¹⁴S(O)q-L-, R¹⁴S(O)qNH-L-, o R¹⁴C(O)NH-L-; R¹⁴ es RᵃRᵇN-, alquiloC₁₋₆, alqueniloC₂₋₆, alquiniloC₂₋₆, haloalquiloC₁₋₆, alcoxiC₁₋₆, haloalquiloC₁₋₆, haloalcoxiC₁₋₆, o R⁵-L¹-; q, r, t, y w se seleccionan independientemente para cada aparición entre 0, 1 y 2; y v se selecciona independientemente para cada aparición entre 0, 1, 2 y 3.
ARP210101072A 2020-04-22 2021-04-21 Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv AR121905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063014001P 2020-04-22 2020-04-22

Publications (1)

Publication Number Publication Date
AR121905A1 true AR121905A1 (es) 2022-07-20

Family

ID=75919388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101072A AR121905A1 (es) 2020-04-22 2021-04-21 Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv

Country Status (13)

Country Link
US (1) US20230183213A1 (es)
EP (1) EP4139292A1 (es)
JP (1) JP2023523241A (es)
KR (1) KR20230005881A (es)
CN (1) CN115843294A (es)
AR (1) AR121905A1 (es)
AU (1) AU2021261307A1 (es)
BR (1) BR112022021419A2 (es)
CA (1) CA3180706A1 (es)
IL (1) IL297305A (es)
MX (1) MX2022013251A (es)
TW (1) TW202206415A (es)
WO (1) WO2021216656A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023067518A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. Process
WO2023069547A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3085368A1 (en) 2011-07-01 2016-10-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
WO2013010069A1 (en) 2011-07-13 2013-01-17 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
AR089671A1 (es) 2012-01-06 2014-09-10 Janssen R & D Ireland 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
PL2890683T3 (pl) 2012-08-28 2017-06-30 Janssen Sciences Ireland Uc Pochodne skondensowanego bicyklicznego sulfamylu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
TWI696606B (zh) 2012-08-28 2020-06-21 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基-芳醯胺類及其做為治療ｂ型肝炎之醫藥劑的用途
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN105051017A (zh) 2012-11-09 2015-11-11 美国印第安纳大学研究和技术公司 用于hbv组装效应剂的替代用途
CN110642741A (zh) 2012-12-06 2020-01-03 巴鲁克斯布隆伯格研究所 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
CA2896554C (en) 2012-12-27 2019-11-05 Drexel University Novel antiviral agents against hbv infection
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SI2997019T1 (sl) 2013-05-17 2018-12-31 Janssen Sciences Ireland Uc, Derivati sulfamoiliofenamida in njihova uporaba kot zdravila za zdravljenje hepatitisa B
EA201592126A1 (ru) 2013-05-17 2016-05-31 Ф. Хоффманн-Ля Рош Аг 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
KR102244937B1 (ko) * 2013-07-25 2021-04-27 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 글리옥사미드 치환된 피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
WO2015138895A1 (en) * 2014-03-13 2015-09-17 Indiana University Research And Technology Corporation Hepatitis b core protein allosteric modulators
TWI721016B (zh) * 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
BR112018067964B1 (pt) * 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
ES2817426T3 (es) * 2016-06-29 2021-04-07 Novira Therapeutics Inc Derivados de oxadiazepinona y su uso en el tratamiento de infecciones por hepatitis B
CN109937201A (zh) * 2016-09-15 2019-06-25 组装生物科学股份有限公司 乙型肝炎核心蛋白调节剂

Also Published As

Publication number Publication date
KR20230005881A (ko) 2023-01-10
WO2021216656A1 (en) 2021-10-28
EP4139292A1 (en) 2023-03-01
JP2023523241A (ja) 2023-06-02
CA3180706A1 (en) 2021-10-28
IL297305A (en) 2022-12-01
BR112022021419A2 (pt) 2023-03-07
CN115843294A (zh) 2023-03-24
MX2022013251A (es) 2022-11-14
TW202206415A (zh) 2022-02-16
AU2021261307A1 (en) 2022-11-17
US20230183213A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
AR121905A1 (es) Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv
AR117102A1 (es) Inhibidores de arg1 y/o arg2
AR117616A1 (es) Compuestos anti-vih
AR120684A1 (es) INHIBIDORES DE HIF-2a
BRPI0518424B8 (pt) derivados de 2,4 (4,6) pirimidina, composição farmacêutica que os compreende, intermediários e uso dos mesmos
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR107714A1 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR108875A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR114972A1 (es) Compuestos
AR124369A1 (es) Inhibidores de prmt5 novedosos
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR045687A1 (es) Macrociclos derivados de la quinazolina, procesos de preparacion y composiciones farmaceuticas que los contienen
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR112290A1 (es) Dinucleótidos cíclicos como agentes anticáncer
AR117424A1 (es) Inhibidores de los receptores erbb
AR037770A1 (es) Compuesto inhibidor de la integrasa del vih, composicion farmaceutica que lo comprende y uso del mismo para prepararla
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
AR112187A1 (es) Compuesto de 2-oxo-benzo[d]oxazol-6-sulfonamida, composición farmaceutica que lo comprende y su uso para la fabricación de un medicamento
AR124048A1 (es) Inhibidores de la btk
AR123962A1 (es) Inhibidores de interleucina-17
JP2018502137A5 (es)
AR124172A1 (es) Compuesto de heteroarilcarboxamida
AR127308A1 (es) Inhibidores ras